- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 66
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease
- Interventions
- Femoral Nerve Block
- Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Crisis
- Interventions
- Care pathway
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 5,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- crizanlizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 12
- States / cities
- Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more
- Conditions
- Sickle Cell Disease
- Interventions
- sodium nitrite injection, usp
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 23 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease
- Interventions
- SelG1, Placebo
- Drug
- Lead sponsor
- Reprixys Pharmaceutical Corporation
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
- Conditions
- Sickle Cell Crisis, Sickle Cell Disease
- Interventions
- Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Crovalimab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • New York, New York
- Conditions
- Sickle Cell Disease
- Interventions
- Mometasone Furoate, Placebo
- Drug
- Lead sponsor
- Jeffrey Glassberg
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Nirmish Shah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- Ticagrelor, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more
- Conditions
- Sickle Cell Disease
- Interventions
- ICA-17043
- Drug
- Lead sponsor
- Icagen
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Suvankar Majumdar
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sickle Cell Disease
- Interventions
- Crizanlizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more
- Conditions
- Sickle Cell Disease
- Interventions
- Prasugrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Hemoglobin SC Disease, Sickle Cell Anemia
- Interventions
- Recombinant-methionyl human stem cell factor
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Virtual Reality Therapy
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Anemia, Sickle Cell
- Interventions
- Rivipansel, Placebo
- Drug · Other
- Lead sponsor
- Biossil Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 126
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
- Conditions
- Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat tablets
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Cerritos, California • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- SANGUINATE, Placebo
- Drug
- Lead sponsor
- Prolong Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 9
- States / cities
- Hollywood, Florida • Tampa, Florida • Baltimore, Maryland + 5 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Varespladib, Placebo (Normal Saline)
- Drug · Other
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sickle Cell Disease
- Interventions
- BEAM-101
- Biological
- Lead sponsor
- Beam Therapeutics Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 14 more
- Conditions
- Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
- Interventions
- Intranasal ketamine
- Drug
- Lead sponsor
- Abigail Nixon
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- The Bronx, New York
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis
- Interventions
- Ketamine hydrochloride injection, Placebo
- Drug · Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 24 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts